Brokerages Set GeoVax Labs, Inc. (NASDAQ:GOVX) Target Price at $14.20

GeoVax Labs, Inc. (NASDAQ:GOVX) has received an average rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.20.

GOVX has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a research note on Friday, November 15th. Alliance Global Partners began coverage on GeoVax Labs in a report on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research note on Friday, January 31st.

Institutional Trading of GeoVax Labs

A number of large investors have recently bought and sold shares of GOVX. Virtu Financial LLC acquired a new position in GeoVax Labs during the 3rd quarter worth approximately $97,000. Geode Capital Management LLC boosted its holdings in shares of GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the last quarter. Northern Trust Corp acquired a new stake in GeoVax Labs during the 4th quarter valued at $29,000. Finally, Citadel Advisors LLC acquired a new stake in GeoVax Labs during the 4th quarter valued at $104,000. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Price Performance

Shares of GeoVax Labs stock opened at $1.68 on Wednesday. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The company’s fifty day moving average price is $2.08 and its two-hundred day moving average price is $2.66.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.